The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"The market is growing for greenhouses since farmers are now noticing that biostimulants are becoming a must. In my opinion, it's quite impossible to produce high-quality, healthy, and safe food in a greenhouse without dealing with crop stress as a critical issue that needs to be managed.
In the Spanish market, we already see that biostimulants are as important for greenhouse growers as irrigation or nutrition is. The stress will always be there; nothing can change that; you have to reduce and manage it."
https://news.agropages.com/News/NewsDetail---49407.htm
Crazy mon, UK Plc up for sale, on the plus side Spirent did have a few few UK funds invested.
The three catalysts in my playbook are:
- Ingenuity, strategic investor (symbiotic)
- Interest rates/inflation down followed by trackers
- Merging of Premium and Standard listing followed by more trackers
Goliath iShares fund, consumer desc still at 3rd place
https://www.ishares.com/uk/professional/en/products/244049/ishares-core-msci-eafe-etf
Short positions in China stocks shrink after regulatory crackdown
PUBLISHED SAT, MAR 2 20248:58 PM EST
https://www.cnbc.com/2024/03/03/short-positions-in-china-stocks-shrink-after-regulatory-crackdown.html
Its hindsight now of course, but perhaps if the board had rejected the previous bids but left the door ajar we may have seen further suitors courting THG, instead everyone knows its not for sale so no point trying, hence (in part) low valuation.
Hutchmed is a good comparison as its share structure is very similar, large institutional (c70%) base backing current management, this makes any bids difficult to get through.
Its feeding on itself now, UK fund managers ditching UK stocks due to poor performance favouring US tech instead, its now become self fulfilling.
One or two quotes worth reading;
Britain For Sale: The country's biggest firms are being picked off 'one by one' as foreign predators pounce
https://www.thisismoney.co.uk/money/markets/article-13142677/Britain-Sale-countrys-biggest-firms-picked-one-one-foreign-predators-pounce.html
Is this why UK media have stopped picking on UK business, whoops what have we done..
ICL Accelerating Biologicals Portfolio Growth in Brazil with Strategic Acquisition
Company adding meaningful manufacturing capabilities and expanding product portfolio with acquisition of Nitro 1000
https://www.businesswire.com/news/home/20240227911936/en/ICL-Accelerating-Biologicals-Portfolio-Growth-in-Brazil-with-Strategic-Acquisition
Couple of brief articles:
According to a recently compiled report from Market.us, the biostimulant market size is forecast to exceed $5.6 billion (USD) by 2033. This reflects significant growth from its estimated value of $2.7 billion (USD) in 2023. The expected growth would equate a compound annual growth rate of 7.5% from 2024 to 2033.
https://news.agropages.com/News/NewsDetail---49145.htm
***************************************************
Brazil’s surge in biopesticide use marks a sustainable agriculture shift
Over the last five years, Brazil has witnessed a 45% yearly increase in biopesticide use.
This growth far exceeds the 6% seen in traditional agricultural chemicals. Now, biopesticides cover 70 million hectares in Brazil.
https://news.agropages.com/News/NewsDetail---49362.htm
Inflation data as expected, could be getting close on some central banks stepping back.
https://www.cnbc.com/2024/02/29/wall-street-takes-bets-on-which-major-central-bank-will-blink-first.html
..nah, don't buy that Jatw, those are good numbers, prop traders trying to dampen enthusiasm is my guess.
Modest growth at SHPL but a very nice asset indeed, are they looking at a possible separate IPO ?
> We continue to explore opportunities to monetize the underlying value of our SHPL joint venture including various divestment and equity capital market alternatives.
AstraZeneca sets global strategic center in Shanghai
https://www.chinadaily.com.cn/a/202402/28/WS65de87a6a31082fc043b972f.html
If THG is still left behind when rates/inflation drop then yes, totally agree something must give but right now I think its all about coming out the other side, horrendous HFD statement today.
New Ingenuity partner to replace Softbank is highly likely imo, that should help.
Sorry, that was meant to read:
- That said, I still don't think an actual bid will materialise as THG is not for sale, that much we do know.-
Its worth reading Matt's post for context:
https://www.linkedin.com/posts/matthew-moulding_nothanks-pe-onwards-activity-7062681230554591233-gaz_
Hornby steaming ahead, now Direct Line.
That said, I still think an actual bid will materialise as THG is not for sale, that much we do know.
For anyone perplexed by THG's current valuation, take a look at Hutchmed (HCM) - released cracking results today, almost half market cap in cash but again, not an easy bid target due to CK Hutchison Holdings Limited conglomerate owning nearly 40%.
'Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million'
https://www.lse.co.uk/rns/HCM/2023-full-year-results-and-business-updates-01yxizr6d6rmgb2.html
Its not just THG..